The Weight Loss Drug Nobody Chose for Weight Loss
Gil Solano, a registered EEG technologist, provides a thorough breakdown of topiramate (brand name Topamax) in this video with 42,000 views. Topiramate occupies a strange position in the weight loss space. It was developed and approved as an anti-seizure medication. Then clinicians noticed that patients on topiramate were losing weight as a side effect. Eventually, topiramate was combined with phentermine to create Qsymia, an FDA-approved weight management drug. Understanding topiramate matters for anyone comparing weight loss medication options because it remains one of the most commonly prescribed drugs that causes weight loss, even though GLP-1 medications have largely displaced it as the preferred pharmacological approach.
This video is not specifically framed as a weight loss discussion. It covers topiramate thoroughly, including its primary uses for epilepsy and migraine prevention. But the weight loss mechanism and side effect profile are the aspects most relevant to the GLP-1 audience, and Gil Solano covers them with the detail they deserve.
How Topiramate Causes Weight Loss
Topiramate's weight loss mechanism is multifactorial and not as cleanly understood as GLP-1 receptor agonism. The drug modulates several neurotransmitter systems simultaneously: it enhances GABA activity (the brain's primary inhibitory neurotransmitter), blocks certain glutamate receptors (reducing excitatory signaling), inhibits carbonic anhydrase enzymes, and affects voltage-gated sodium and calcium channels. The combined effect of these actions on the brain centers that regulate appetite and food reward produces meaningful appetite suppression.
The carbonic anhydrase inhibition is thought to contribute specifically to appetite reduction by altering taste perception. Many topiramate patients report that food, particularly sweet and carbonated foods, tastes different or less appealing. Carbonated beverages in particular can taste flat or metallic. This altered taste perception reduces the hedonic pleasure of eating, which in turn reduces caloric intake.
Clinical trials of topiramate for weight loss showed average weight reductions of 5-7% of body weight as a standalone medication, comparable to Contrave and older weight loss drugs. When combined with phentermine in Qsymia, the weight loss increases to approximately 8-10% of body weight, which was considered impressive before GLP-1 medications reset the bar.
The Side Effect Profile That Limits Its Use
Gil Solano dedicates significant time to topiramate's side effects, and for good reason. This is where the drug's drawbacks become most apparent, especially compared to the relatively manageable side effect profile of GLP-1 medications. The most commonly reported side effect is cognitive impairment, so prevalent that patients and physicians have nicknamed the drug "Dopamax" because it can make you feel cognitively dull. Word-finding difficulties, impaired concentration, reduced processing speed, and memory issues are reported by a substantial percentage of patients.
For people taking topiramate for seizure control, these cognitive effects may be an acceptable tradeoff for seizure freedom. For people taking it primarily for weight loss, accepting cognitive impairment in exchange for modest weight reduction is a much harder sell, especially when GLP-1 alternatives exist that do not affect cognition.
Paresthesias (tingling sensations in the hands, feet, and face) are another common side effect, caused by the carbonic anhydrase inhibition that affects peripheral nerve function. These are usually not dangerous but can be uncomfortable and persistent. Kidney stones are a more serious concern: topiramate increases the risk of calcium phosphate kidney stones through its effects on urinary pH and citrate excretion. Adequate hydration is essential for patients on topiramate, and patients with a history of kidney stones may be advised against the drug entirely.
Metabolic acidosis (a shift toward lower blood pH) occurs in some patients and can be clinically significant, particularly at higher doses. Acute angle-closure glaucoma, while rare, is a potential ophthalmic emergency associated with topiramate that requires immediate medical attention if sudden eye pain, vision changes, or eye redness occur.
Topiramate vs. GLP-1 Medications: The Direct Comparison
The comparison is not particularly close for most weight management patients. GLP-1 medications produce greater weight loss (15-22% vs. 5-10%), have a better-understood mechanism specific to metabolic regulation, produce improvements in cardiovascular risk markers that topiramate does not, and have a side effect profile dominated by GI symptoms that typically improve over time rather than cognitive symptoms that may persist throughout treatment.
Where topiramate retains relevance is in specific clinical scenarios. Patients with both obesity and epilepsy benefit from a single medication that addresses both conditions. Patients with obesity and migraine headaches similarly benefit from topiramate's dual indication. Patients who cannot access or afford GLP-1 medications may find topiramate (which is available as an inexpensive generic) an accessible alternative. And the combination product Qsymia may be prescribed for patients who need weight loss support but are not candidates for GLP-1 therapy.
The phentermine/topiramate combination (Qsymia) is worth understanding because it represents a different pharmacological strategy: combining two drugs with moderate individual weight loss efficacy to produce a combined effect that approaches the lower range of GLP-1 outcomes. Phentermine provides sympathomimetic appetite suppression (like a milder amphetamine), while topiramate contributes its own appetite and taste-modifying effects. The combination is effective for many patients but carries the side effect burdens of both drugs.
Important Safety Information
Gil Solano covers several safety points that are critical for anyone prescribed topiramate. The drug is teratogenic, meaning it can cause birth defects if taken during pregnancy. Specifically, topiramate is associated with an increased risk of cleft lip and cleft palate in infants exposed during the first trimester. Women of childbearing age must use effective contraception while taking topiramate, and the drug should be discontinued before planned pregnancy.
The cognitive effects of topiramate are dose-dependent: higher doses produce more cognitive impairment. For weight management (where lower doses are typically used compared to epilepsy treatment), the cognitive effects may be milder, but they should still be monitored. Patients whose work or lifestyle requires sharp cognitive function (surgeons, pilots, professional drivers, students) should weigh this carefully.
Abrupt discontinuation of topiramate can trigger seizures in patients with epilepsy and may cause withdrawal symptoms in non-epileptic patients. The drug should always be tapered gradually under medical supervision rather than stopped suddenly. This applies even to patients taking topiramate solely for weight loss who decide to discontinue treatment.
Where Things Stand in the Current Space
Topiramate's role in weight management has shrunk considerably since GLP-1 medications became widely available. It remains a useful tool for specific patient populations, particularly those with comorbid conditions (epilepsy, migraine) that topiramate also treats, and those who need an affordable generic option. But for the average patient seeking pharmaceutical weight loss support, GLP-1 medications have become the clear first-line recommendation based on superior efficacy and a more favorable side effect profile.
Gil Solano's thorough breakdown is valuable because it gives patients and caregivers a complete picture of the drug. If you have been prescribed topiramate or Qsymia, or if your physician has discussed it as an option, this video provides the context you need to have an informed conversation about whether it is the right choice for your situation. If you are comparing it to GLP-1 options, the data is clear: GLP-1 medications produce better weight loss outcomes for most patients, but topiramate fills a niche for patients where GLP-1 therapy is not available, not affordable, or not appropriate.
Who Should Consider Topiramate Today
Despite its limitations compared to GLP-1 medications, topiramate remains a reasonable consideration for several specific patient profiles. Patients already taking topiramate for epilepsy or migraine prevention who also need weight management benefit from the dual-purpose nature of the drug. Adding a separate weight loss medication on top of topiramate adds complexity, cost, and potential drug interactions that may not be necessary if topiramate itself is providing adequate weight control.
Patients with binge eating disorder may also benefit from topiramate. Several studies have shown that topiramate reduces binge eating frequency and severity, possibly through its effects on glutamate signaling and reward processing. This application is off-label but is used by psychiatrists and obesity specialists who treat eating disorders alongside weight management. The combination of reduced binge frequency and modest weight loss can be clinically meaningful for this population.
Financial accessibility remains a significant advantage. Generic topiramate costs $10-30 per month at most pharmacies, and generic Qsymia (phentermine/topiramate extended-release) is also available at moderate cost. For patients whose insurance does not cover GLP-1 medications and who cannot afford $800-1,400 per month out of pocket, topiramate-based options represent an affordable entry point into pharmacological weight management. The effectiveness gap compared to GLP-1 drugs is real, but some pharmacological support is better than no pharmacological support for patients who have failed lifestyle intervention alone.
Monitoring requirements for topiramate include periodic blood work to check bicarbonate levels (to detect metabolic acidosis), kidney function, and electrolytes. Eye exams should be performed if any visual symptoms develop. Cognitive function should be assessed regularly, and patients should be encouraged to report any word-finding difficulties, memory problems, or concentration changes promptly so dose adjustments can be made before cognitive impairment becomes significant.
For patients considering topiramate specifically because GLP-1 medications are not accessible, it is worth understanding that topiramate works best when combined with structured lifestyle changes. The medication provides modest appetite reduction that makes it easier to adhere to a calorie-reduced diet, but without deliberate dietary and exercise modifications, the weight loss results tend to be at the lower end of the range seen in clinical trials. Treating topiramate as a complement to behavioral changes rather than a replacement for them produces the best outcomes in real-world clinical practice.